Related Experiment Video
Updated: Jul 13, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Targetability of human disease genes
Meena K Sakharkar1, Kishore R Sakharkar
1Advanced Design and Modeling Lab, Nanyang Technological University, Singapore.
Current Drug Discovery Technologies
|July 17, 2007
Summary
Computational biology aids in identifying human disease genes that are both druggable and disease-modifying. This approach offers systematic in silico drug target identification in the post-genomic era.
Area of Science:
- Genomics
- Computational Biology
- Pharmacology
Background:
- Complete genome sequences and large biological datasets offer new ways to understand human disease genetics.
- Identifying effective therapeutic targets requires them to be both druggable and capable of modifying disease progression.
Purpose of the Study:
- To review the use of computational biology in assessing the druggability, targetability, and evolutionary conservation of human disease genes.
- To highlight the potential of these computational analyses for systematic drug target identification.
Main Methods:
- Review of computational biology applications.
- Analysis of genomic data.
- Assessment of evolutionary conservation of disease genes.
Main Results:
- Computational biology methods can systematically explore druggability and targetability of disease genes.
- Evolutionary conservation analysis provides insights into the functional importance of disease genes.
Conclusions:
- Computational biology is a powerful tool for identifying potential drug targets in the post-genomic era.
- Integrating genomic data with computational analysis can accelerate the discovery of disease-modifying therapies.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:16In-vitro Mutagenesis
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.